265 related articles for article (PubMed ID: 15504568)
1. Calcium and vitamin D supplementation during bisphosphonate administration may increase osteoclastic activity in patients with bone metastasis.
Altundag O; Altundag K; Selim Silay Y; Gunduz M; Demircan K; Gullu I
Med Hypotheses; 2004; 63(6):1010-3. PubMed ID: 15504568
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates: clinical experience.
Coleman RE
Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases.
Amir E; Simmons CE; Freedman OC; Dranitsaris G; Cole DE; Vieth R; Ooi WS; Clemons M
Cancer; 2010 Jan; 116(2):284-91. PubMed ID: 19918922
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.
Chirgwin JM; Guise TA
Crit Rev Eukaryot Gene Expr; 2000; 10(2):159-78. PubMed ID: 11186331
[TBL] [Abstract][Full Text] [Related]
5. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
Conte P; Guarneri V
Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
[TBL] [Abstract][Full Text] [Related]
6. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM
Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872
[TBL] [Abstract][Full Text] [Related]
7. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
[TBL] [Abstract][Full Text] [Related]
8. Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment.
Polyzos SA; Anastasilakis AD; Makras P; Terpos E
Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):519-24. PubMed ID: 21811962
[TBL] [Abstract][Full Text] [Related]
9. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.
Clines GA; Guise TA
Endocr Relat Cancer; 2005 Sep; 12(3):549-83. PubMed ID: 16172192
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of bisphosphonates.
Green JR
Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms and treatment of hypercalcemia of malignancy.
Clines GA
Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221
[TBL] [Abstract][Full Text] [Related]
12. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
13. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.
Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Fontana D; Angeli A
J Urol; 2001 Dec; 166(6):2023-31. PubMed ID: 11696699
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer bone metastasis and current small therapeutics.
Cicek M; Oursler MJ
Cancer Metastasis Rev; 2006 Dec; 25(4):635-44. PubMed ID: 17160709
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates.
Wang-Gillam A; Miles DA; Hutchins LF
Oncologist; 2008 Jul; 13(7):821-7. PubMed ID: 18614589
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates in oncology.
Coleman RE; McCloskey EV
Bone; 2011 Jul; 49(1):71-6. PubMed ID: 21320652
[TBL] [Abstract][Full Text] [Related]
17. New results from the use of bisphosphonates in cancer patients.
Coleman R; Gnant M
Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Saad F; Lipton A
BJU Int; 2005 Nov; 96(7):964-9. PubMed ID: 16225510
[TBL] [Abstract][Full Text] [Related]
19. Bone health in men with prostate cancer: diagnostic and therapeutic considerations.
Saad F; Perrotte P; Bénard F; McCormack M; Karakiewicz PI
Can J Urol; 2005 Jun; 12 Suppl 2():9-15. PubMed ID: 16018826
[TBL] [Abstract][Full Text] [Related]
20. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Saad F; McKiernan J; Eastham J
Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]